Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

VOLUNTARY ANNOUNCEMENT
QYUNS' INDUSTRIALIZATION BASE SUCCESSFULLY PASSES EU QP AUDIT

This announcement is made by Qyuns Therapeutics Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors (the "**Board**") of the Company is pleased to announce that Jiangsu Cellularforce Biopharma Co., Ltd. ("**Cellularforce**"), a subsidiary of the Company, successfully passed the EU Qualified Person ("**QP**") audit and officially received the compliance audit report issued by the QP. The successful passing of the QP audit signifies that the quality management system and production capacity of the Group's industrialization base have met EU GMP standards.

The audit was conducted by a senior QP in accordance with EudraLex Volume 4 (EU GMP regulations for pharmaceuticals) and related guidelines. A comprehensive three-day review of Cellularforce was carried out, during which the audit team fully recognized Cellularforce's high-standard quality management system, advanced facilities and equipments, and professional technical team, and confirmed that both the software and hardware management of the production base comply with EU GMP requirements. Enterprises that pass the QP inspection will receive a declaration of compliance issued by the QP, which serves as strong evidence of the enterprise's compliance with international GMP requirements and is a prerequisite for products to enter the EU market.

Receiving the QP certification is a significant milestone in the global expansion strategy for the Group's products, laying a solid foundation for the future overseas launch of the Company's innovative products and its global market penetration.

ABOUT THE EU QP SYSTEM

The EU GMP first introduced the QP system in 1975. Nearly five decades of successful practical experience have demonstrated that this system is an advanced quality management model to effectively ensure drug quality, and has become one of the core components of the EU GMP system.

The EU has stringent requirements for QP qualifications. The legal status, qualifications and responsibilities of the QP are detailed in the European Commission Directive 2001/83/EC and Annex 16 of the Good Manufacturing Practice Guide, "Certification by a Qualified Person and Batch Release". The professional expertise and extensive experience of QPs make them experts and authorities in the pharmaceutical industry.

ABOUT CELLULARFORCE

Established in 2018, Cellularforce is committed to providing partners with high-quality, one-stop and customized biologics CDMO services that comply with NMPA, FDA and EMA standards. Its services cover the entire chain from molecule design and evaluation, process development, clinical sample production, analysis and quality control, regulatory registration and submission, to commercial production, aiming to help partners accelerate the research and development of innovative drugs, reduce production costs, and facilitate the early availability of more high-quality biologics for patients worldwide.

By order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan
Chairman of the Board and Executive Director

Hong Kong, October 10, 2025

As of the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive Directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.